Reviewers report polarized outcomes: some patients see modest results, many see no measurable response and request a switch to injectables
placebo: 2% (1/51), 95% CI: 010%) and AEs leading to discontinuation (apitegromab: 4% (2/51), 95% CI: 113%
Even in aggressive scenarios for reduced consumption related to GLP-1 use, modest gains to life expectancy can more than offset the impact over time. Indeed, because obesity-related diseases cut years off average lifespans, treatment with GLP-1 drugs can add years (up to 14 years) to the lives of those who take them
What the bill aims to do is to make sure that those ingredients are coming from FDA approved suppliers. Online, the U.S
Wegovy also showed a favorable safety profile
Drug designers are creating multi-agonists that stimulate more than one receptor, potentially amplifying results